AddedRisk Factors
There remains substantial uncertainty as to how the current U.S. administration will seek to or continue to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. This uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates. Furthermore, the U.S. Supreme Court’s June 2024 decision in Loper Bright Enterprises v. Raimondo, which overturned the long-standing Chevron doctrine that required courts to give deference to regulatory agencies’ reasonable interpretations of ambiguous federal statutes, could result in additional legal challenges to regulations and guidance issued by federal agencies, including the FDA, on which we rely. The Loper decision may result in increased regulatory uncertainty, inconsistent judicial interpretations and other impacts to the agency rule-making process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action or as a result of legal challenges, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our business could be materially harmed.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedRisk Factors
In the U.S., there are currently no marketed therapies for the treatment of X-ALD. HSC therapy has been used to treat the most severe form of X-ALD, CALD. More recently, gene therapy has been shown to be effective in CALD, and elivaldogene autotemcel from
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedRisk Factors
Moreover, our contract manufacturers may experience difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our contract manufacturers were to encounter any of these difficulties, our ability to provide our product candidates to participants in preclinical and clinical trials, or to provide product for treatment of participants if approved, would be jeopardized.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedRisk Factors
Moreover, we have no control over the ability of our third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any comparable foreign regulatory authority does not authorize the manufacture of any of our current or future product candidates at these facilities or if it withdraws any such authorization in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market any of our current or future product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of any of our current or future product candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of any of our current or future product candidates.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RemovedRisk Factors
In addition, our CROs may need to make certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA on March 18, 2020 and generally, and may need to make further adjustments in the future. Many of these adjustments are new and untested, may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring and in-licensing technologies and products complementary to our programs or advantageous to our business.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the PPACA, was enacted. The PPACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Changes in government funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, properly administer drug innovation, or prevent our product candidates from being developed or commercialized, which could negatively impact our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
In December 2016, the 21st Century Cures Act was signed into law. This legislation is designed to advance medical innovation and empower the FDA with the authority to directly hire positions related to drug and device development and review. However, government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA and other related government agencies. These budgetary pressures may result in a reduced ability by the FDA to perform its roles, including the related impact to academic institutions and research laboratories whose funding is fully or partially dependent on both the level and timing of funding from government sources.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
The European Data Protection Board continues to release guidelines for industries and impose fines related to the GDPR, some of which have been very significant. To improve coordination among EU supervisory authorities, the European Commission has proposed a new regulation that would help to streamline enforcement of the GDPR in cross-border cases. Meanwhile, there continues to be persistent uncertainty relating to the transfer of personal data from Europe to the U.S., or other non-adequate countries, following the Schrems II decision. On July 10, 2023, the European Commission adopted its adequacy decision on the EU-U.S. Data Privacy Framework, or DPF. The decision, which took effect on the day of its adoption, concludes that the United States ensures an adequate level of protection for personal data transferred from the EEA to companies certified to DPF. However, it remains too soon to tell how the future of DPF will evolve and what impact it will have on our international activities. At least one challenge to the DPF is pending before the Court of Justice of the European Union.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Further, Brexit has led and could also lead to legislative and regulatory changes that may increase our compliance costs. As of January 1, 2021 and the expiry of transitional arrangements agreed to between the UK and the EU, data processing in the UK is governed by a UK version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which authorizes similar fines and other potentially divergent enforcement actions for certain violations. On June 28, 2021, the European Commission adopted an Adequacy Decision for the UK, allowing for the relatively free exchange of personal data between the EU and the UK (as the UK correspondingly allows transfers back to the EU). However, the European Commission may suspend the Adequacy Decision if it considers that the UK no longer provides for an adequate level of data protection. A bill to amend the existing UK framework has been reintroduced (in a different form) by the new UK Government and was announced as a bill which will be introduced into Parliament at the King’s Speech on July 17, 2024. At this time, there is no specific clarity on the provisions of the bill, or the extent to which it will amend the UK framework, beyond general descriptions on its intended purpose.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Additionally, new laws also are being considered at both the state and federal levels and several states have passed comprehensive privacy laws. For example, the California Consumer Privacy Act, or the CCPA, which went into effect on January 1, 2020, is creating similar risks and obligations as those created by the GDPR, though the CCPA does exempt certain clinical trial data. The California Privacy Rights Act, or the CPRA, which went into effect on January 1, 2023, amended and expanded the CCPA, and also created a new state agency that is vested with authority to implement and enforce the CCPA and the CRPA. The CCPA and the CRPA may increase our compliance costs and potential liability, and we cannot yet predict the impact of the CCPA or the CRPA on our business. Similar laws passed in Virginia, Colorado, Connecticut, and Utah took effect in 2023 while laws in Oregon, Montana and Texas went into effect in 2024. Additionally, Delaware, Florida, Indiana, Iowa, Kentucky, Maryland, Minnesota, Nebraska, New Hampshire, New
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our ability to effectively monitor and respond to the rapid and evolving developments and expectations relating to sustainability, including environmental, social and governance matters, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
There is an increasing focus from certain investors, employees, regulators, listing exchanges and other stakeholders concerning corporate responsibility and sustainability matters, including with regarding environmental, social and governance factors. Some investors and investor groups may use these factors—either positively or negatively—to guide their investment strategies and, in some cases, investors may choose not to invest in our company if they believe our policies or practices relating to corporate responsibility and sustainability do not align with their expectations. Currently, a number of third-party providers of corporate responsibility and sustainability ratings measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and some major institutional investors have publicly emphasized the importance of these measures to their investment decisions. Topics taken into account in such assessments include, among others, companies’ efforts and impacts on climate change, human rights, business ethics and compliance, diversity, equity and inclusion and the role of companies’ board of directors in overseeing various sustainability-related issues. In light of investors’ increased focus on these matters, if we are, for example, perceived as lagging in taking steps with respect to these initiatives, certain investors may seek to engage with us on improving our corporate responsibility and sustainability disclosures or performance. They may also make voting decisions or take other actions to hold us and our board of directors accountable.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, there are rapidly evolving developments and changing expectations relating to sustainability matters. As a result, the criteria by which our corporate responsibility and sustainability practices are assessed may change, which could cause us to undertake costly initiatives or actions to satisfy new demands. If we elect not to or are unable to adequately recognize and respond to such developments and changing governmental, societal, investor and/or consumer expectations relating to sustainability matters, we may miss corporate opportunities, become subject to additional scrutiny or incur unexpected costs. We may face risk of litigation or reputational damage in the event that our sustainability policies or practices do not meet the standards set by various constituencies.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may also face reputational damage if we are unable to achieve an acceptable rating from third-party rating services. A low rating by a third-party rating service could also result in the exclusion of our common stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate responsibility and sustainability matters by investors and other stakeholders as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, financial condition, or results of operations, including the sustainability of our business over time, and could cause the market value of our common stock to decline.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
Since our incorporation in September 2012, our operations have been limited to raising capital, building infrastructure, obtaining the worldwide rights to certain technology from Ligand Pharmaceuticals Incorporated, or Ligand, and planning, preparing and conducting preclinical studies and clinical trials of our drug candidates, including VK2735 subcutaneous, VK2735 oral, VK2809, VK5211 and VK0612, which are currently in Phase 2 clinical development, VK0214, for which we recently completed a Phase 1b clinical trial, trial; as well as the dual amylin and calcitonin receptor agonist, or DACRA, diacylglycerol acyltransferase-1, or DGAT-1 and erythropoietin receptor, or EPOR, programs, which are each currently in preclinical development.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Since our incorporation in September 2012, our operations have been limited to raising capital, building infrastructure, obtaining the worldwide rights to certain technology from Ligand Pharmaceuticals Incorporated, or Ligand, and planning, preparing and conducting preclinical studies and clinical trials of our drug candidates, including VK2735 subcutaneous, VK2735 oral, VK2809, VK5211 and VK0612, which are currently is in Phase 2 clinical development, VK0214, for which we recently completed a Phase 1b clinical trial, as well as the dual amylin and calcitonin receptor agonist, or DACRA, diacylglycerol acyltransferase-1, or DGAT-1 and erythropoietin receptor, or EPOR, programs, which are each currently in preclinical development. 3 development;
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, and in June 2025, we plan to advance announced the initiation of our VANQUISH Phase 3 program for the subcutaneous formulation and in August 2025, we announced positive top-line results from our Phase 2 clinical trial of VK2735 into Phase 3 development. the oral tablet formulation of VK2735.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, we are aware of numerous development-stage programs targeting this disease, including arachidyl amido cholanoic acid from Galmed Pharmaceuticals Ltd., belapectin from Galectin Therapeutics Inc., lanifibranor from Inventiva S.A., semaglutide and efruxifermin (AKR-001) from Novo Nordisk A/S, firsocostat (GS-0976) and cilofexor (GS-9674) from Gilead Sciences, Inc., tirzepatide from Eli Lilly and Company, ervogastat (PF-06865571) and clesacostat (PF-05221304) PF-07853578 from Pfizer Inc., efruxifermin (AKR-001) from Akero Therapeutics, Inc., pegozafermin (BIO89-100) from 89bio, Inc., denifanstat (TVB-2640) from Sagimet Biosciences Inc., efocipegtrutide (HM15211) from Hanmi Pharmaceutical Co., Ltd., survodutide (BI 456906) from Boehringer Ingelheim International GmbH, ION224 and ION839 from Ionis Pharmaceuticals, Inc., rencofilstat (CRV431) from Hepion Pharmaceuticals, Inc., HTD1801 from HighTide Therapeutics Inc., efimosfermin alfa and GSK4532990 (ARO-HSD) from GlaxoSmithKline plc., ALN-HSD rapirosiran (ALN-HSD) from Alnylam Pharmaceuticals, Inc./ Regeneron Pharmaceuticals Inc., efinopegdutide (MK-6024) from Merck & Co., Inc., and pemvidutide (ALT-801) from Altimmune, Inc., pegozafermin (BIO89-100) from Hoffmann-La Roche Ltd, and ALG-055009 from Aligos Therapeutics, Inc.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, or the EU, including personal health data, is subject to the EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or the EEA, in May 2018.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
There Although we believe that there will be a significant cash pay market for obesity drugs, there certainly would be a much larger obesity market with reimbursement from third-party payors and likely no viable commercial market for our other drug candidates, if approved, without reimbursement from third-party payors.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Accordingly, If we undergo one or more ownership changes in connection with any future transactions in our stock, our ability to utilize our net operating loss carryforwards to offset federal taxable income, if any, will likely be limited by Section 382, which could potentially result in increased future tax liability to us. liability.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
We continue to monitor any adverse impact that the outbreak of war in Ukraine, the subsequent institution of sanctions against Russia by the United States these and several European and Asian countries, and the Israel-Hamas war other geopolitical conflicts may have on the global economy in general, on our business and operations and on the businesses and operations of our suppliers and other third parties with which we conduct business.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
We will also face competition from these third parties in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring and in-licensing technologies and products complementary to our programs or advantageous to our business.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
As For our DACRA program, as of December 31, 2024, for our GLP-1 program, 2025, we own one U.S. patent, PCT application and additional patents in certain foreign jurisdictions, two PCT applications, and several patent applications in the U.S. and certain foreign jurisdictions.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Undesirable side effects observed in clinical trials or in supportive preclinical studies with our drug candidates could interrupt, delay or halt their development and Such findings could result in the denial of regulatory approval by the FDA, EMA or comparable foreign authorities for any or all targeted indications or adversely affect the marketability of any such drug candidates that receive regulatory approval.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our The failure by us, or our third-party vendors, to comply with these regulations may require subject us or them to enforcement or other legal actions or other consequences, such as requiring us to repeat clinical trials, which would delay the development and regulatory approval processes.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Even if If we ultimately receive regulatory approval for any of these drug candidates, we or our potential future partners, if any, may be unable to commercialize them successfully for a variety of reasons.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We do not have a sales and marketing organization, and we have no limited experience as a company in the sales, marketing and distribution of pharmaceutical products.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We currently in-license most some of our intellectual property rights to develop our drug candidates and may in-license additional intellectual property rights in the future.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As the UPC is a relatively new court system, there is no little precedent for the court, increasing the uncertainty of any litigation.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In June 2025, we announced the initiation of two Phase 3 clinical studies to evaluate the subcutaneous formulation of VK2735, VANQUISH-1 and VANQUISH-2. In November 2025, we announced completion of enrollment in the VANQUISH-1 study.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In January 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and in August 2025, we announced positive top-line results from the trial. The Phase 2 VENTURE-Oral Dosing trial successfully achieved its primary and secondary endpoints, with patients receiving oral VK2735 demonstrating statistically significant reductions in body weight compared with placebo. Additionally, the trial showed oral VK2735 treatment to be safe and well-tolerated through 13 weeks of daily dosing with the majority of treatment emergent adverse events being categorized as mild or moderate. We expect to initiate Phase 3 Oral dosing studies in the third quarter of 2026.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, we announced the initiation of an exploratory Phase 1 maintenance dosing study of VK2735. This study is intended to explore the feasibility of various VK2735 maintenance dosing regimens utilizing either the oral tablet or the subcutaneous formulation to sustain the initial weight loss achieved following subcutaneous dosing. In January 2026, we announced completion of enrollment in this study.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In 2024, we announced a new, internally developed Dual Amylin and Calcitonin Receptor Agonist, or DACRA, program for the treatment of obesity and highlighted the effects of treatment on body weight, food intake and metabolic profile in both healthy rats and in diet-induced obese mice. The results demonstrated that our DACRAs reduced food intake in lean rats in the period from 0 – 72 hours following a single subcutaneous dose. We plan to file an Investigational New Drug, or IND, application for this program in the first quarter of 2026.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In March 2025, we entered into broad, multi-year manufacturing agreements, or the Manufacturing Agreements, with Corden Pharma Colorado, Inc. and its affiliates, or CordenPharma, covering both the active pharmaceutical ingredient, or API, and final finished product supply for VK2735.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
Under the terms of the Manufacturing Agreements, we have secured dedicated capacity for the annual manufacture and supply of multiple metric tons of VK2735 API. In addition, CordenPharma will provide fill/finish capacity for both the injectable and oral formulations of VK2735. This includes dedicated manufacturing lines and an annual commitment to supply 100 million autoinjectors and an additional 100 million vial and syringe products for the subcutaneous formulation, as well as an annual capacity of over one billion oral VK2735 tablets. These API and final finished product capacities are further expandable at Viking’s option. In exchange for dedicated API and fill/finish capacity, we will make prepayments to CordenPharma, to be paid over the period from 2026 to 2028. These prepayments will be fully credited against future orders.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In 2024, we announced a new, internally developed Dual Amylin and Calcitonin Receptor Agonist, or DACRA, program for the treatment of obesity and highlighted the effects of treatment on body weight, food intake and metabolic profile in both healthy rats and in diet-induced obese mice. The results demonstrated that our DACRAs reduced food intake in lean rats in the period from 0 – 72 hours following a single subcutaneous dose. We plan to file an Investigational New Drug, or IND, application for this program in the first quarter of 2026.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
We manage and prioritize our research and development expenses dynamically based on scientific data, probability of successful technical development and regulatory approval, market potential and unmet medical need, available human and capital resources and
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
other considerations. We regularly review our research and development activities and, as necessary, reallocate resources among our programs, product candidates and external opportunities that we believe will best support the long-term growth of our business. We do not track total research and development expenses by program, product candidate, or development phase.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
(in thousands) December 31, 2025 December 31, 2024 Personnel, facility and equipment, and other overhead costs $28,525 $19,392 Clinical and other development costs $316,430 $82,252 Total $344,955 $101,644
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
Net cash provided by (used in) investing activities $341,388 $ (553,366) $ (179,086)
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RemovedMD&A
On January 8, 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, our dual agonist of the GLP-1 and GIP receptors. We expect to complete this study and report initial results in the second half of 2025.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
The increase decrease in general and administrative expenses during the year ended December 31, 2024 2025 as compared to the year ended December 31, 2023 2024 was primarily due to decreased legal and patent services of $8.8 million, partially offset by increased expenses related to stock-based compensation, compensation of $6.9 million, insurance of $0.6 million and salaries and benefits, professional fees, insurance and services provided by third-party consultants, partially offset by decreased legal and patent services. benefits of $0.3 million.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Research and development costs primarily consist of fees paid to contract research organizations, or CROs, and clinical trial sites, employee and consultant related expenses, which include salaries, benefits and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in research and development expenses during the year ended December 31, 2024 2025 as compared to the year ended December 31, 2023 2024 was primarily due to increased expenses related to clinical studies of $202.7 million, manufacturing for our drug candidates, candidates of $32.5 million, stock-based compensation and of $4.2 million, salaries and benefits, benefits of $3.7 million, regulatory services of $0.4 million and consultants of $0.3 million, partially offset by a decrease in expenses related to clinical preclinical studies and preclincal studies. of $1.0 million.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2023, 2025, net cash used in provided by investing activities of $179.1 $341.4 million resulted from the purchase of investments of $478.3 million, offset by the proceeds of maturities of investments of $299.2 $759.4 million, offset by the purchase of investments of $418.0 million.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, net cash used in operating activities of $87.8 $278.7 million primarily reflected our net losses for the period, adjusted by non-cash charges such as stock-based compensation, amortization of investment premiums, amortization of right-of-use assets, realized gain on investment, amortization of financing costs, realized gain on investment and interest expense related to operating lease liabilities as well as changes in our working capital accounts, primarily consisting of an increase in accounts payable, accrued expenses, accounts payable expenses and accrued interest, net of interest received on maturity of investments, partially offset by decreases in prepaid expenses and other assets and lease liability.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
We also expect general and administrative expenses to increase as a result of additional costs associated with continue to include expenses related to be being a public company, including expenses related to compliance with the rules and regulations of the SEC and The Nasdaq Stock Market LLC, additional insurance expenses, investor relations activities and other administration and professional services.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
The primary endpoint of the study evaluated the relative change in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction from baseline to week 12 in subjects treated with VK2809 as compared to placebo.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Since our incorporation, we have devoted most of our efforts towards conducting certain clinical trials and preclinical studies related to our VK2735 subcutaneous, VK2735 oral, DACRA, VK2809, VK0214, VK0214 and VK5211 and dual amylin and calcitonin receptor agonist programs and towards raising capital and building infrastructure.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, $ % Change Change 2025 2024 2023 General and administrative expenses $ 49,277 $37,021 $12,256 33.1% 48,387 $49,277 $ (890) (1.8
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Other income, net recognized during the years ended December 31, 2025 and 2024 and 2023 consisted primarily of interest income, income and realized gain on investments, partially offset by expense relating to the amortization of certain financing costs.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
From the date of the ATM Prospectus through December 31, 2024, 1,426,303 2025, 3,556,911 shares of our common stock were sold pursuant to the ATM Offering and, as of December 31, 2024, 2025, we may sell shares of our common stock for remaining gross proceeds of up to $151.9 $75.7 million from time to time pursuant to the ATM Prospectus.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
Quiet changesMD&A
VK5211 demonstrated encouraging safety and tolerability in this study, with no drug-related SAEs serious adverse events reported.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new